Acute Promyelocytic Leukemia
A highly curable but initially deadly leukemia subtype marked by severe bleeding (DIC) and driven by a genetic mutation (t(15;17)) treated with a Vitamin A derivative.
Emergency Management: Severe DIC leading to uncontrollable bleeding. Immediate treatment involves ATRA and massive blood product support (cryoprecipitate/FFP).
Acute Promyelocytic Leukemia (APL) is a distinct, aggressive subtype of acute myeloid leukemia (AML) characterized by a block in myeloid differentiation at the promyelocyte stage. It is genetically defined by a balanced reciprocal translocation between chromosomes 15 and 17, t(15;17)(q24;q21), which creates the PML-RARA fusion gene. Clinically, it frequently presents with life-threatening disseminated intravascular coagulation (DIC).
Detailed Overview
APL is a medical emergency. The pathognomonic PML-RARA fusion protein binds retinoic acid receptors and actively represses gene transcription necessary for myeloid differentiation, filling the marrow with heavily granulated promyelocytes. These granules contain procoagulants (tissue factor) that, when released, trigger explosive consumption coagulopathy (DIC). The advent of All-Trans Retinoic Acid (ATRA) revolutionized APL, making it the most curable subtype of adult AML. ATRA overrides the repressor effect, inducing the malignant cells to terminally differentiate into mature neutrophils.
Epidemiology & Demographics
Accounts for 10-15% of all adult AML cases. Median age of onset is 40 years. Higher incidence in individuals of Hispanic or Latin American descent.
Etiological Mechanism
Acquired genetic mutation: t(15;17) translocation fusing the Promyelocytic Leukemia (PML) gene to the Retinoic Acid Receptor Alpha (RARA) gene.
Primary Causes
Malignant clonal expansion of promyelocytes due to transcriptional blockade caused by the PML-RARA fusion oncoprotein.
Normal RARA binds retinoic acid to activate genes for white blood cell maturation. The t(15;17) translocation creates the PML-RARA oncoprotein, which acts as a dominant-negative repressor, halting differentiation at the promyelocyte stage. These immature promyelocytes accumulate in the bone marrow, crowding out normal hematopoiesis (causing pancytopenia). Their prominent cytoplasmic granules (Auer rods) contain highly active thromboplastin-like substances. Upon cell death or chemotherapy initiation, release of these substances rapidly initiates both coagulation and intense primary fibrinolysis, resulting in disastrous hemorrhagic complications.
Diagnostic Criteria & Guidelines
Presumptive diagnosis is based on bone marrow morphology (hypergranular promyelocytes with multiple Auer rods, 'faggot cells'). Definitive diagnosis requires molecular or cytogenetic confirmation of t(15;17) or PML-RARA via FISH or PCR.
Immediate administration of ATRA (All-Trans Retinoic Acid) 45 mg/m2/day in divided doses. Do NOT wait for genetic confirmation if clinical suspicion is high. Co-administer Arsenic Trioxide (ATO) 0.15 mg/kg/day IV for standard-risk APL.
Second-Line & Adjunctive Therapy
High-risk patients (WBC > 10k) receive ATRA + ATO + an anthracycline (e.g., Idarubicin 12 mg/m2 IV days 2, 4, 6, 8) or Gemtuzumab ozogamicin.
Surgical & Procedural Management
None, strictly a hematologic malignancy. Venous access device placement.
Patient Counseling & Advice
Counsel that while APL is an extreme medical emergency initially, it has the highest cure rate of any adult leukemia. Discuss the specific warning signs of Differentiation Syndrome (sudden shortness of breath).
Follow-Up & Monitoring Schedule
Intensive daily monitoring of coagulation labs (PT, PTT, Fibrinogen) and platelets during induction. Transfuse to keep Fibrinogen >150 mg/dL and platelets >50,000/microL until coagulopathy resolves. Monitor ECG for QTc prolongation (caused by ATO).
Preventive Strategies
No primary prevention.
Highly curable. With ATRA and ATO therapy, the complete remission rate is >90%, and long-term overall survival exceeds 85-90%.